Ritter Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
2015年6月24日 - 10:53PM
ビジネスワイヤ(英語)
Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR), a pharmaceutical
company developing novel therapeutic products that modulate the
human gut microbiome to treat gastrointestinal diseases with its
lead product, RP-G28, being developed for the treatment of lactose
intolerance, today announced the pricing of its initial public
offering of 4,000,000 shares of its common stock at a price to the
public of $5.00 per share. All of the common stock is being offered
by Ritter Pharmaceuticals, Inc. The gross proceeds to Ritter
Pharmaceuticals, Inc. from the initial public offering are expected
to be $20,000,000 before deducting underwriting discounts and
commissions and other estimated offering expenses.
Ritter Pharmaceuticals, Inc. has granted the underwriters a
45-day option to purchase up to 600,000 additional shares of common
stock to cover over-allotments, if any. The common stock of Ritter
Pharmaceuticals, Inc. has been approved for listing on The NASDAQ
Capital Market and is expected to begin trading under the ticker
symbol "RTTR" on June 24, 2015. The offering is expected to close
on June 29, 2015, subject to customary closing conditions.
Aegis Capital Corp. is acting as sole book-running manager for
the offering.
Chardan Capital Markets, LLC is acting as lead manager and
Barrington Research is acting as co-manager for the offering.
A registration statement relating to these securities has been
filed with the Securities and Exchange Commission and declared
effective on June 24, 2015.
This offering is being made only by means of a prospectus.
Copies of the prospectus relating to the offering may be obtained
by contacting Aegis Capital Corp., Prospectus Department, 810
Seventh Avenue, 18th Floor, New York, NY 10019, via telephone:
212-813-1010, or via e-mail: prospectus@aegiscap.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Ritter Pharmaceuticals, Inc.
Ritter Pharmaceuticals, Inc. develops novel therapeutic products
that modulate the human gut microbiome to treat gastrointestinal
diseases. Ritter Pharma is advancing human gut health research by
exploring the metabolic capacity of gut microbiota and translating
the functionality of these microbiome modulators into safe and
effective applications. Ritter Pharma’s lead drug candidate,
RP-G28, has the potential to become the first FDA-approved drug for
lactose intolerance, a condition that affects more than one billion
people worldwide.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150624005865/en/
Investor and Media:LHAJody Cain, jcain@lhai.comBruce
Voss, bvoss@lhai.com(310) 691-7100orRitter Pharmaceuticals,
Inc.Susan Rogerssusan@ritterpharma.com650-430-3777
Ritter Pharmaceuticals (NASDAQ:RTTR)
過去 株価チャート
から 6 2024 まで 7 2024
Ritter Pharmaceuticals (NASDAQ:RTTR)
過去 株価チャート
から 7 2023 まで 7 2024